COMMENTARY - US Pharmacopeial Convention
COMMENTARY - US Pharmacopeial Convention
COMMENTARY - US Pharmacopeial Convention
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>COMMENTARY</strong>– <strong>US</strong>P 32-NF 27 Second Supplement<br />
is recommended that this test be performed on the Active Pharmaceutical Ingredient<br />
(API) rather than drug product.<br />
Comment Summary #6: The commenters indicated that the column specified in the<br />
procedure should be removed from the General Chapter because the column is no<br />
longer manufactured.<br />
Response: Comment not incorporated because the appropriate column is commercially<br />
available.<br />
Comment Summary #7: The commenters indicated that the quality of the heparinases<br />
is one of the major uncontrolled variables and therefore suggested that <strong>US</strong>P could<br />
either qualify such materials or provide them as Reference Standards.<br />
Response: Comment not incorporated because the quality of heparinases is controlled<br />
by the system suitability requirements described in the procedure.<br />
Comment Summary #8: The commenter suggested including High Performance Liquid<br />
Chromatography (HPLC) system parameters in order to ensure reproducible results<br />
between laboratories.<br />
Response: Comment not incorporated because the <strong>US</strong>P Enoxaparin Sodium<br />
Reference Standard and the associated reference chromatogram provide the<br />
appropriate controls for reproducible results between laboratories.<br />
Comment Summary #9: The commenter indicated that the concentration of acetic acid<br />
used in the method is not specified.<br />
Response: Comment incorporated to specify glacial acetic acid.<br />
Comment Summary #10: The commenter indicated that the storage conditions for<br />
material after depolymerization are not specified.<br />
Response: Comment incorporated to specify storage conditions.<br />
Comment Summary #11: The commenter indicated that the volume specified for<br />
exposure to sodium borohydride is difficult to transfer to an HPLC vial because foaming<br />
occurs upon mixing; therefore, the sample requires centrifuging before transferring to<br />
the HPLC vial.<br />
Response: Comment not incorporated because gentle mixing minimizes foaming.<br />
Comment Summary #12: The commenter suggested including requirements for<br />
expiration dates and storage conditions for mobile phases, buffers, and enzyme<br />
cocktail.<br />
Response: Comment not incorporated because expiration dates and storage conditions<br />
are manufacturing documentation and labeling requirements for regulated products.<br />
General Chapter/Section(s): Residual Solvents/Other Analytical Procedures<br />
Expert Committee(s): General Chapters<br />
No. of Commenters: 1<br />
Comment Summary #1: The commenter indicated retaining Methods I, IV, V, and VI<br />
because the Methods are used to quantitate residual solvents in approved marketed<br />
products.<br />
Response: Comment not incorporated because no supporting data was provided,<br />
indicating that these methods provide the necessary specificity and sensitivity for<br />
quantitation of the solvents listed in the current version of General Chapter <br />
Residual Solvents.<br />
- 4 -